<DOC>
	<DOCNO>NCT00549601</DOCNO>
	<brief_summary>This study use two dos rivastigmine transdermal patch ( 5 cm^2 , 10 cm^2 ) establish feasibility 2 switch schedule ( transdermal patch one-step dose titration without dose titration ) rivastigmine capsule ( 3 mg bid ( bi die , twice day ) , 4,5 mg bid , 6 mg bid ) rivastigmine transdermal patch ass safety , tolerability , convenience , caregiver preference rivastigmine transdermal patch versus capsule .</brief_summary>
	<brief_title>Convenience , Tolerability , Safety Change Administration Rivastigmine From Capsules Transdermal Patch Patients With Mild Moderate Alzheimer 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Rivastigmine</mesh_term>
	<criteria>Meet DSMIV ( Diagnostic &amp; Statistical Manual Mental Disorders , Version IV ) criteria dementia Alzheimer type NINCDSADRDA ( National Institute Neurological Communicative Disorders Stroke Alzheimer 's Disease Related Disorders Association ) criteria probable Alzheimer 's disease ( AD ) , MMSE ( Mini Mental State Examination ) score &gt; 10 &lt; 26 Have receive continuous treatment rivastigmine capsule least 3 mg bid ( 6 mg total daily dose ) least 3 month enter study Cooperative , willing complete aspect study , capable , either alone aid responsible caregiver Have primary caregiver willing accept responsibility supervise treatment , ( eg , application removal patch daily approximately time day ) assess condition patient throughout study . A medical neurological condition AD could explain patient dementia ( eg , Huntington 's disease , Parkinson 's Disease , abnormal thyroid function test , B12 folate deficiency , posttraumatic condition , syphilis ) Current diagnosis active skin lesion/disorder would prevent accurate assessment adhesion potential skin irritation patch ( e.g. , atopic dermatitis , wound scratch skin area patch application ) History allergy topical product contain vitamin E Taken follow substance prior randomization : succinylcholinetype muscle relaxant previous 2 week investigational drug previous 4 week Other protocoldefined inclusion/exclusion criterion apply study .</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>Alzheimer 's</keyword>
	<keyword>rivastigmine</keyword>
	<keyword>transdermal</keyword>
	<keyword>safety</keyword>
	<keyword>randomize</keyword>
	<keyword>switch</keyword>
	<keyword>patch</keyword>
</DOC>